Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment (TIME) and significantly improved anti-tumor responses in preclinical models of pancreatic cancer.
In this study, published today in Nature Cancer, researchers used comprehensive immune...
In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology (ASH) Annual Meeting. These oral presentations highlight encouraging results to advance the use of targeted therapies and novel combinations in multiple types of leukemia, including high-risk and newly diagnosed acute myeloid leukemia (AML) in older and younger patients...
ABSTRACT 63
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with SNDX...
ABSTRACTS 62, 82, 95, 199, 232, 540, 708, 766, 960
The University of Texas MD Anderson Cancer Center’s Research Highlights provides...
Christopher Flowers, M.D., division head ad interim of Cancer Medicine and chair of Lymphoma & Myeloma at The University of Texas MD Anderson...
ABSTRACTS GS1-07, GS5-08, PD6-11, HER2-01
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse...